Mandate

Vinge has advised Gränges in connection with its rights issue

Vinge has advised Gränges AB (publ) in connection with a fully guaranteed rights issue of approximately SEK 1.7 billion before transaction costs.

The purpose of the rights issue is to finance the acquisition of Aluminium Konin, maintain Gränges’ financial strength and to finance future growth investments in line with Gränges’ strategy. The new shares subscribed for with subscription rights are expected to be admitted to trading on Nasdaq Stockholm on December 22, 2020.

Gränges is a leading global supplier of rolled aluminium products for heat exchanger applications, speciality packaging and niche markets. The company develops, produces and markets advanced materials that enhance efficiency in the customers’ manufacturing process and the performance of the final products. The company’s geographical markets are Europe, Asia and the Americas with production facilities in all three regions and a total annual capacity of 560,000 metric tonnes. Gränges has 2,400 employees and net sales of SEK 13 billion. The share is listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Jesper Schönbeck, Rikard Lindahl, Linnéa Sellström, Stephanie Stiernstedt, Anders Sundin Lundberg and Lorin Arabi (Capital Markets and Public M&A), Pauline Lagerstrand and Rebecka Målquist (Banking and Finance) as well as Maria Schultzberg and Henrik Wastenson (Tax).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026